Home › Malattia epatica steatosica › Virginia › Richmond
Studi clinici su Malattia epatica steatosica a Richmond, VA
12 studi su Malattia epatica steatosica cercano partecipanti presso sedi a Richmond e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
In reclutamentoFase 3
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
In reclutamentoFase 3
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
In reclutamentoFase 2
- Virginia Commonwealth University, Richmond
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
In reclutamentoFase 2
- Richmond Veterans Administration Medical Center, Richmond
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
In reclutamentoFase 3
- Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
- Virginia Commonwealth University (VCU) Medical Center, Richmond
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
In reclutamentoFase 3
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- e altri 1
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
In reclutamentoFase 2
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
In reclutamentoFase 2
- GSK Investigational Site, Richmond
- GSK Investigational Site, Richmond
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
In reclutamentoFase 2
- GSK Investigational Site, Richmond
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
In reclutamentoFase 2
- Virginia Commonwealth University, Richmond
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
In reclutamento
- Virginia Common wealth University, Richmond
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
In reclutamentoStudio osservazionale
- Virginia Commonwealth University, Richmond
Studi su Malattia epatica steatosica in altre città
- San Antonio, TX17 studi
- New York City, NY16 studi
- Miami, FL16 studi
- San Diego, CA14 studi
- Austin, TX13 studi
- Houston, TX13 studi
- Tucson, AZ10 studi
- Chandler, AZ10 studi
- Hialeah, FL9 studi
- Dallas, TX9 studi
- Orlando, FL9 studi
- St. Louis, MO9 studi
Altri studi a Richmond
- Cancro al seno26 studi
- Cancro del polmone non a piccole cellule25 studi
- Cancro alla prostata19 studi
- Insufficienza cardiaca16 studi
- Cancro ai polmoni14 studi
- Malattie cardiovascolari13 studi
- Cancro colorettale13 studi
- Leucemia mieloide acuta12 studi
- Cancro metastatico12 studi
- Carcinoma a cellule squamose della testa e del collo12 studi
- Melanoma11 studi
- Obesità11 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.